be identified: C282Y and HLA-A3/B7 haplotype, H63D and HLA-A29/B44 haplotype, and S65C and HLA-A26 haplotype. 3 The aims of this work are (1) to study whether the IVS2ϩ4TϾC variant may have a hemochromatosis phenotypic effect, and (2) to study whether this variant is in linkage disequilibrium with HLA alleles or haplotypes.
We studied 65 Spanish probands with a presumptive diagnosis of hemochromatosis that were heterozygous for C282Y and negative for H63D and S65C. In addition, 86 unrelated, apparently healthy subjects were used as controls for the study. Finally, 23 individuals homozygous for the C282Y mutation and 31 for the H63D mutation were used in the study.
The HFE typing for the C282Y, H63D, and S65C mutations was performed as previously described. 3 The HFE typing for the IVS2ϩ4TϾC variant used the PCR-RFLP technique with the following primers: HFE2BF (CTTTGGGCTACGTGGATGACC) and HFE2BR (AAGCTCTGACAACCTCAGGAAGG). The IVS2ϩ4TϾC variant creates a RsaI site and the 239 base pairs (bp) PCR product digested with this enzyme was cut into two fragments of 197 and 42 bp. HLA-class I typing was performed by the standard complement-dependent microlymphocytotoxicity assay using commercially available alloantisera. Allele and haplotype frequencies were estimated using Arlequin V2.0 software. 4 The allele frequency of the IVS2ϩ4TϾC variant was statistically different in the control group (34.8%) from that in the heterozygous group for the C282Y mutation (16.2%), P ϭ 0.009. When we typed for IVS2ϩ4TϾC in 23 individuals homozygous for C282Y, none of them carried the intronic variant, indicating that the presence of the C282Y mutation excludes the presence of the IVS2ϩ4TϾC variant in the same chromosome. Thus, the real frequency of the intronic variant in the heterozygous group for the C282Y mutation is 32.4%, which is not statistically different from the control group. If IVS2ϩ4TϾC were involved in generating a HH phenotype, we would expect to find an increased frequency of this variant in the heterozygous group for the C282Y mutation. In addition, we have found 10 (11.4%) individuals homozygous for the IVS2ϩ4TϾC variant in the apparently healthy group, leading us to think that this intronic variant is not a mutation that produces hemochromatosis.
The second aim of this work was to study the linkage disequilibrium of the IVS2ϩ4TϾC variant with HLA alleles and haplotypes. When we compared the HLA allelic and haplotypic frequencies of individuals homozygous for the IVS2ϩ4TϾC variant (n ϭ 20) with individuals negative for this variant (n ϭ 70), we found an increased frequency of the HLA-A29/B44 haplotype in the group of individuals homozygous for the IVS2ϩ4TϾC variant (20% vs. 1.4%, P ϭ 0.008). It has been demonstrated that HLA-A29/B44 haplotype is in linkage disequilibrium with the H63D mutation. 3, 5 Next, we asked ourselves whether HLA-A29/B44_H63D_IVS2ϩ4TϾC is an extended haplotype or if there are two different A29/B44 haplotypes: one carrying the IVS2ϩ4TϾC variant and the other carrying the H63D mutation. To answer this question, we studied the IVS2ϩ4TϾC variant in a group of 31 individuals homozygous for the H63D mutation. All of them turned out to be homozygous for the intronic variant while only 65% of chromosomes carrying the intronic variant were positive for the H63D mutation. This observation, together with the allele frequencies of H63D (20%) and IVS2ϩ4TϾC (34.8%) in the normal population, allow us to think that IVS2ϩ4TϾC is probably older than H63D.
In conclusion, our results suggest the IVS2ϩ4TϾC variant is probably not a HH mutation. In addition, we have found the IVS2ϩ4TϾC variant is in linkage disequilibrium with the HLA-A29/B44 haplotype and is older than the H63D mutation.
